Amarin Corporation plc (AMRN) AI Stock Analysis

Amarin Corporation plc develops and distributes therapies for cardiovascular diseases across global markets such as the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its primary product is VASCEPA, a prescription omega-3 fatty acid drug used alongside diet to lower triglyceride levels in adult patients with severe hypertriglyceridemia. Amarin distributes its products primarily through wholesalers and specialty pharmacies. In addition, Amarin maintains a strategic partnership with Mochida Pharmaceutical Co., Ltd. to develop and commercialize products and indications derived from eicosapentaenoic acid, the active pharmaceutical ingredient in VASCEPA.

Amarin has experienced sustained top-line declines, reflected in a 5-year revenue CAGR of -19.0% from FY2020 to FY2025. Annual revenue decreased from $583.2M in FY2021 to $213.6M in FY2025, where revenue fell 6.5%. Operating margins fluctuated from 1.8% in FY2021 to -40.2% in FY2024 before improving to -6.5% in FY2025. Net income was -$38.8M in FY2025 with an EPS of $0.27, following a net loss of -$82.2M in FY2024. For the latest quarter ended June 30, 2026, quarterly revenue fell 42.0% year-over-year and quarterly earnings declined 94.2%, bringing trailing twelve-month revenue to $186.2M with a net profit margin of -14.6%.

As of June 30, 2026, Amarin held $314.6M in cash and short-term investments against $5.3M in total debt, resulting in net cash of $309.4M. Its liquidity profile is supported by a current ratio of 3.67 and a debt-to-equity ratio of 0.01 on total shareholders' equity of $443.6M. Operating cash flow and free cash flow both reached $6.7M in FY2025, recovering from -$31.0M in FY2024. Over the past five years, the company's share count increased by 3.7%.

Amarin has a market capitalization of $237.4M and an enterprise value of -$21.7M due to its net cash position. The stock trades at a forward P/E of 500.0x, well above the 17.3x median of its US-listed Healthcare peers. Its price-to-sales multiple of 1.3x and price-to-book multiple of 0.7x sit below the peer group median price-to-sales ratio of 4.1x. Over the past year, Amarin shares declined 43.6%, lagging the S&P 500 return of 16.8%. Over five years, the stock is down 89.0% compared to an 83.0% gain for the S&P 500.

Two covering analysts track Amarin, issuing zero Buy or Hold ratings, one Sell rating, and one Strong Sell rating. The mean price target of $12.50 implies an upside of 10.4% from the last close of $11.32. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $177.4M and an EPS of -$0.07. For the following fiscal year, estimates project revenue of $176.8M and an EPS of -$0.06. Over the last four quarters, Amarin beat EPS estimates twice. The next earnings announcement is scheduled for November 4, 2026.

This page is an AI-written research summary of Amarin Corporation plc (AMRN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: AMRN income statement, AMRN balance sheet, AMRN key metrics, AMRN analyst forecast, AMRN chart. See the AMRN stock overview for the latest quote and news.